Official and regulatory announcements from Abera Bioscience, including financial reports, clinical trial updates, and material corporate events.
Abera Bioscience and Orexo AB are entering into a collaboration to develop and test Abera’s vaccine candidates in powder formulations. Abera develops mucosal vaccines based on its innovative vaccine platforms and has a pipeline of several preclinical vaccine candidates. Orexo specializes in drug formulations and has a unique formulation technology,
Abera Bioscience (“Abera” or “the Company”) presents very promising results from a comparative study where their pneumococcal vaccine candidate, Ab-01.12, was compared to the world-leading vaccine, Prevnar 13, and studied in combination with it. The study demonstrates that Abera’s vaccine is 1,000 times more effective in preventing colonization (growth) of
Abera Bioscience AB (“Abera” or “the company”) has received the final decision to approve its patent application “Display of heterologous molecules on bacterial cells and membrane vesicles” from the European Patent Office (EPO). The patent covers several effective methods for decorating cells or bacterial vesicles (OMVs) with different particles. It
FINANSIELL ÖVERSIKT TREDJE KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 3 348 (0) kSEK Resultatet efter finansiella poster uppgick till -278 (-4 186) kSEK. Resultat per aktie: -0,02 (-0,32) SEK. Soliditeten uppgick till 86 (78) %. FINANSIELL ÖVERSIKT FÖRSTA NIO MÅNADERNA 2024 Nettoomsättningen uppgick
Abera Bioscience (“Abera” or “the Company”), the world’s leading biotechnology company in mucosal vaccines, announces that it is starting in vivo studies for its new nasal influenza vaccine candidate. The studies are funded by the grant from CEPI – Coalition for Epidemic Preparedness Innovations, which the company previously announced in
OSLO/STOCKHOLM, 28 october 2024 Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against epidemic and pandemic threats. Supported by a new CEPI grant of up to US$1 million, Abera Bioscience will investigate the role of bacterial outer membrane
Abera Bioscience AB (“Abera” or “the Company”) has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal vaccine, Ab-01.12, towards clinical trials. The vaccine, which is based on the Abera’s OMV platform, is administered as a nasal spray and designed to provide
Abera Bioscience AB (“Abera”) is advancing its vaccine candidates, utilizing its proprietary Outer Membrane Vesicles (OMVs) and Protein Bodies platforms. One indication in the growing pipeline of pre-clinical vaccine candidates is Chlamydia, a widespread sexually transmitted infection with no current vaccine. Today, promising results from the research of PhD Tan
FINANSIELL ÖVERSIKT ANDRA KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 506 (44) kSEK Resultatet efter finansiella poster uppgick till -665 (-5 742) kSEK. Resultat per aktie: -0,04 (-0,44) SEK. Soliditeten uppgick till 79 (69) %. FINANSIELL ÖVERSIKT FÖRSTA HALVÅRET 2024 Nettoomsättningen uppgick till
The Annual General Meeting 2024 of Abera Bioscience AB (“Abera” or the “Company”) was held on June 12, 2024 and made the following decisions: Approval of the Income Statement and Balance Sheet The Annual General Meeting resolved to approve the income statement and balance sheet of Abera. Appropriation of Profits